Future studies will be instrumental in documenting how vulnerability to MYC blockage could be exploited to potentiate other RTK targeting agents already approved in HCC, including sorafenib, lenvatinib, and regorafenib. The gene discussed is MYC; the disease is hepatocellular carcinoma.